Shapiro et al. review how microbial signals modulate immune responses across tissues to regulate metabolic homeostasis and cardiometabolic diseases. They discuss mechanisms linking the microbiome, immunity, and tissue function and present emerging microbiome-based interventions for disease prevention and treatment.
A compelling longitudinal study of over 350 older adults with early beta-amyloid accumulation reveals that the genetic risk for Alzheimer’s disease is not strictly deterministic, but is profoundly modulated by sleep quality through the AQP4 gene—a critical regulator of the brain’s glymphatic waste-clearance system. By cross-referencing specific AQP4 variants with multi-year MRI and PET imaging alongside cognitive assessments, researchers demonstrated that poor sleep parameters, such as shorter duration and delayed onset, significantly accelerate neurodegenerative markers like gray matter loss and ventricle expansion in carriers of specific risk alleles. Paradoxically, however, carriers of certain rare variants exhibited slower cognitive decline even in the presence of sleep disturbances. Ultimately, these findings illuminate a complex gene-environment interplay, proving that identical genetic predispositions can either expedite or buffer against brain atrophy depending on sleep architecture, thereby highlighting the critical necessity of personalized, sleep-targeted lifestyle interventions as a highly actionable strategy for Alzheimer’s prevention.
Scientists have discovered an important link between sleep, genetics, and Alzheimer’s disease. New findings suggest that getting poor sleep can accelerate brain shrinkage and memory loss in older adults carrying specific genetic variants.
Self-amplifying RNA is synthetic nucleic acid engineered to replicate within cells without generating viral particles. Derived from alphavirus genomes, saRNA retains the non-structural elements essential for replication while replacing the structural elements with an antigen of interest. By enabling efficient intracellular amplification, saRNA offers a promising alternative to conventional mRNA vaccines, enhancing antigen expression while requiring lower doses. However, this advantage comes with challenges. In this review, we highlight the key limitations of saRNA technology and explore potential strategies to overcome them. By identifying these challenges, we aim to provide insights that can guide the future design of saRNA-based therapeutics, extending their potential beyond vaccine applications.
Self-amplifying RNA is synthetic nucleic acid engineered to replicate within cells without generating viral particles. Derived from alphavirus genomes, saRNA retains the non-structural elements essential for replication while replacing the structural elements with an antigen of interest. By enabling efficient intracellular amplification, saRNA offers a promising alternative to conventional mRNA vaccines, enhancing antigen expression while requiring lower doses. However, this advantage comes with challenges. In this review, we highlight the key limitations of saRNA technology and explore potential strategies to overcome them. By identifying these challenges, we aim to provide insights that can guide the future design of saRNA-based therapeutics, extending their potential beyond vaccine applications.
Toscana virus (TOSV), a sandfly-borne virus, is an important etiological agent in human acute meningitis and meningoencephalitis in the Mediterranean area during the summer. However, the actual number of TOSV infections is underestimated. Laboratory confirmation is necessary because TOSV infection has overlapping clinical features with other neuro-invasive viral infections. Nowadays, the reference test for direct diagnosis in the acute phase of TOSV infection is the PCR based method for detecting TOSV in cerebrospinal fluid and/or plasma, serum, or blood. Although poorly employed, urine is another helpful biological matrix for TOSV detection. Urine is a matrix rich in PCR inhibitors that affect PCR efficiency; consequently, false negatives could be generated.
A new study presents an artificial intelligence system that scans images of the retina to detect signs of diabetes, high blood pressure, high cholesterol, gout, osteoporosis and thyroid disease in seconds. The program—called Reti-Pioneer—is a step toward being able to diagnose many different conditions from a scan of the eye, providing people a quicker diagnosis for common conditions and increasing access to crucial testing.
Associate Professor Lisa Zhuoting Zhu, head of ophthalmic epidemiology at CERA, is one of the leading authors on the paper published in Nature Medicine. She says this technology is making disease diagnosis more efficient, particularly in remote or regional communities.
“This technology will be a real benefit to public health,” says Zhu. “Patients would be able to get information about their health instantly and start interventions as soon as possible instead of waiting for more time-consuming test results.”
A night without sleep produced increased markers of connections between brain cells, showing that sleep in humans may be important for restoring cellular balance in the brain, according to a study published in PLOS Biology by David Elmenhorst from the Forschungszentrum Jülich Institute of Neuroscience and Medicine in North Rhine-Westphalia, Germany, and colleagues.
Scientists have long wondered why humans and other animals need to sleep. One potential mechanism is that sleep is required to restore synaptic connections and homeostasis in the brain. Synapses—the connections between brain cells—become stronger during wakefulness.
This increases the amount of energy the brain needs and leads to a buildup of proteins in the brain. Sleep is thought to reset these levels, reducing synaptic connections and restoring homeostasis, but evidence has thus far been limited to animal models.
Physical pain is essential for survival, as it allows animals to detect when they are injured or unwell, seek shelter and address their ailments. Yet when it becomes chronic, pain can also become highly distressing and debilitating.
While there are now several therapeutic strategies for managing chronic pain, an emerging one that has been found to be particularly promising is vagus nerve stimulation (VNS). VNS entails the delivery of mild electrical pulses to the nerve that connects the brain to organs throughout the body.
Past studies suggest that VNS-based therapy can reduce the pain associated with various medical conditions, including chronic headaches, fibromyalgia and joint inflammation. The neural processes by which it can ease pain, however, are still poorly understood.
Researchers from The Hospital for Sick Children (SickKids) in Toronto have found a previously unknown genetic cause of Crohn’s disease and uncovered how those changes trigger inflammation through a key immune pathway. The findings, published in Gastroenterology and involving teams from eight countries, will guide more precise treatments and improve the ability to match patients to therapies based on their unique biology.
“We’ve brought together genetics, RNA sequencing, proteomics and more to try for the first time to map the complete disease pathway, and it’s turned into a remarkable precision medicine story,” says lead author Dr. Aleixo Muise, senior scientist in the Cell & Systems Biology program, staff gastroenterologist and co-director of the Inflammatory Bowel Disease (IBD) Centre at SickKids.
“In our SickKids clinic, we want to find the right drug for each person based on their body’s unique signature. That’s why this paper is so exciting: We have pinpointed a druggable pathway.”